Percutaneous delivery of liquid tetracycline using a thermal resurfacing drug delivery system for the treatment of festoons

被引:0
|
作者
Safir, Margarita [1 ]
Waizer, Inbar [2 ]
Safir, Ari [3 ]
Hartstein, Morris E. [1 ]
Artzi, Ofir [3 ]
机构
[1] Tel Aviv Univ, Fac Med, Shamir Med Ctr, Ophthalmol Dept, Tel Aviv, Israel
[2] Hebrew Univ Jerusalem, Fac Med, Dept Mil Med, Jerusalem, Israel
[3] Tel Aviv Univ, Fac Med, Tel Aviv Sourasky Med Ctr, Div Dermatol, Tel Aviv, Israel
关键词
festoon; tetracycline; Tixel; DOXYCYCLINE; INJECTION;
D O I
10.1002/lsm.23786
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objectives: To examine the effects of percutaneous tetracycline delivery to the malar area using a thermomechanical device (Tixel) in patients suffering from festoons. Methods: This retrospective study included patients who underwent combination treatment with a thermomechanical device (Tixel) followed by application of topical tetracycline 1% at two private clinics between 2019 and 2023. Demographic and medical data, treatment parameters along with before and after treatment photographs were retrieved retrospectively. All patients were asked to answer a questionnaire, assessing self-reported pre and posttreatment disturbance, patient global impression of change (PGIC) score, overall satisfaction with treatment, and the onset and duration of treatment effect. Finally, three masked reviewers evaluated and graded the severity of before and after treatment photographs. Results: Twenty healthy patients received the combination treatment. The mean age was 59.4 +/- 8.2 years (range: 45-72 years), and 90.0% (n = 18) were female. The number of treatment sessions per patient ranged from 2 to 8, mean of 5.0 +/- 1.9, performed at 5.4 +/- 1.2-week intervals. The masked reviewers' grading scores demonstrated a significant improvement (2.81 +/- 1.3 before vs. 1.6 +/- 1.1 after, p < 0.001). The self-reported disturbance caused by the festoons improved significantly as well (4.7 +/- 0.98 vs. 1.7 +/- 1.1, p < 0.001). On the PGIC score, 85% (17/20) reported moderate (grade 5) to significant (grade 7) improvement of symptoms and life quality after treatment. Improvement onset was reported to occur 11.2 +/- 6.6 days after the first treatment (range 2-30 days), and 90% (18/20) of the patients reported improvement lasting at least 4 months after completion of the second treatment. Conclusions: Topical tetracycline application following Tixel treatment induced significant improvement in patient with festoons.
引用
收藏
页码:454 / 461
页数:8
相关论文
共 50 条
  • [1] Enhanced Percutaneous Delivery of Beta-Blockers Using Thermal Resurfacing Drug Delivery System for Topical Treatment of Infantile Hemangiomas
    Mashiah, Jacob
    Bar-Ilan, Efrat
    Koren, Amir
    Friedman, Or
    Zur, Eyal
    Artzi, Ofir
    DERMATOLOGY, 2020, 236 (06) : 565 - 570
  • [2] Percutaneous liquid ablation agent for tumor treatment and drug delivery
    Albadawi, Hassan
    Zhang, Zefu
    Altun, Izzet
    Hu, Jingjie
    Jamal, Leila
    Ibsen, Kelly N.
    Tanner, Eden E. L.
    Mitragotri, Samir
    Oklu, Rahmi
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (580)
  • [3] Bioactive glass as a drug delivery system of tetracycline and tetracycline associated with β-cyclodextrin
    Domingues, ZR
    Cortés, ME
    Gomes, TA
    Diniz, HF
    Freitas, CS
    Gomes, JB
    Faria, AMC
    Sinisterra, RD
    BIOMATERIALS, 2004, 25 (02) : 327 - 333
  • [4] Novel percutaneous adventitial drug delivery system for regional vascular treatment
    Ikeno, F
    Lyons, J
    Kaneda, H
    Baluom, M
    Benet, LZ
    Rezaee, M
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2004, 63 (02) : 222 - 230
  • [5] A novel liquid effervescent floating delivery system for sustained drug delivery
    Ibrahim, Howida Kamal
    DRUG DISCOVERIES AND THERAPEUTICS, 2009, 3 (04): : 168 - 175
  • [6] Chitosan Nanoparticles as a Percutaneous Drug Delivery System for Hydrocortisone
    Katas, Haliza
    Hussain, Zahid
    Ling, Tay Chai
    JOURNAL OF NANOMATERIALS, 2012, 2012
  • [7] A drug delivery system for the treatment of periodontitis
    Weidner, J
    DRUG DISCOVERY TODAY, 2001, 6 (16) : 862 - 863
  • [8] Percutaneous drug delivery using Er:YAG laser
    Tachihara, R
    Farinelli, WA
    Yung, PKL
    Anderson, RR
    LASERS IN SURGERY AND MEDICINE, 2002, : 39 - 39
  • [9] Percutaneous drug delivery using Er:YAG laser
    Tachihara, R
    Farinelli, W
    Lee, P
    Anderson, R
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (02) : 499 - 499
  • [10] Delivery of an epigenetic agent using a microparticle drug delivery system
    Do, Duc P.
    Soluade, Keane O.
    CANCER RESEARCH, 2015, 75